Floatz logo

MODERNA COVID-19 VACCINE RNA

Systemic Sclerosis (SSc)

National Institute of Allergy and Infectious Diseases (NIAID)vaccinePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

24 Active assets in the Systemic Sclerosis (SSc) cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Royal Brompton & Harefield NHS Foundation Trust
Phase 2/3BB
Iloprost
National Center for Research Resources (NCRR)
Phase 3BB
Bosentan
Actelion
Phase 3B
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Royal Brompton & Harefield NHS Foundation Trust
Phase 2/3B
Anti-Thymoglobulin, Rabbit
Fred Hutchinson Cancer Center
Phase 2B

View all 41 →

Same molecule, other indications

MODERNA COVID-19 VACCINE RNA is also rated in:

secondary progressive multiple sclerosisDormant
B
Indicative ·
62 / 100
View asset →
AL amyloidosisDormant
CCC
Indicative ·
55 / 100
View asset →
neoplasmDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →